Onychomycosis Treatment Industry Valued at $5.09 Billion by 2029 With CAGR of 6.7% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What Is the Forecast for the Onychomycosis Treatment Market from 2024 to 2025?#_x000D_
The market size for onychomycosis treatment has experienced significant growth lately. It is expected to rise from $3.65 billion in 2024 to reach $3.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. The expansion during the historic period is likely due to various factors such as an increase in fungal infections, an aging population, heightened public awareness, a surge in onychomycosis cases, and higher disposable incomes._x000D_
_x000D_
#What Is the Projected Market Size of the Onychomycosis Treatment Market?#_x000D_
Expectations are high for a robust expansion in the onychomycosis treatment market in the coming years. The industry is projected to burgeon to a size of $5.09 billion by 2029, with a compound annual growth rate (CAGR) of 6.7%. The forecasted growth can be credited to multiple factors, such as the aging global population, the rise of telemedicine, the advent of combination therapy strategies, easier access to healthcare, alterations in lifestyle choices, environmental aspects, and an increasing proportion of diabetes patients. The significant trends anticipated during this forecast period are developments in dermatology, innovative approaches to drug delivery, personalized therapeutic treatment methods, advances in topical treatments, emerging digital health solutions, and laser therapy techniques._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp_x000D_
_x000D_
#Who are the Major Competitors in the Onychomycosis Treatment Market Outlook?#_x000D_
Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited._x000D_
_x000D_
#What Is Fueling Growth in the Onychomycosis Treatment Market?#_x000D_
The growth of the onychomycosis treatment market is laden with an expected surge due to the rising incidences of fungal infections. These infections are microbial diseases triggered by varying types of fungi resulting in different conditions or affecting various body parts. Onychomycosis, a fungal infection of the nails, is usually treated with oral or topical antifungal medications to eradicate the fungi and promote healthy nail growth. For example, in September 2023, the UK Health Security Agency reported 2,265 cases of bloodstream infections triggered by yeast in England in 2022, as quoted by the SGSS. The overall episode rate of bloodstream infections due to yeast slightly increased to 4.0 per 100,000 people from 3.8 per 100,000 in 2021. Candida albicans (40%), formerly Candida glabrata or Nakaseomyces glabratus (29%), and Candida parapsilosis (13%) were the most frequently identified yeast species in blood specimens. As such, the escalating number of fungal infections is propelling the onychomycosis treatment market’s growth. Further driving the growth of the onychomycosis treatment market is the elevated prevalence of diabetes. This chronic health issue, typified by heightened blood glucose levels, increases the odds of encountering onychomycosis, enhances infection susceptibility, and decelerates the healing process. Topical and laser therapies are instrumental to avoid complications and enhance foot health, hence mitigating the likelihood of ensuing infections. As per the British Diabetic Association (Diabetes UK), around 4.4 million people in the UK were diagnosed with diabetes in 2022-23, a statistic reported in May 2024. Among these cases, about 8% were identified as Type 1 diabetes, whereas about 90% were Type 2 diabetes. The remaining 2% comprises other less prevalent forms of diabetes. Consequently, the growing prevalence of diabetes acts as a major propellant for the onychomycosis treatment market’s expansion._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=12941&type=smp_x000D_
_x000D_
#Which Onychomycosis Treatment Market Segments Are Growing the Fastest?#_x000D_
The onychomycosis treatment market covered in this report is segmented –_x000D_
_x000D_
1) By Type: Distal Sublingual Onychomycosis, White Superficial Onychomycosis, Proximal Sublingual Onychomycosis, Candida Onychomycosis, Other Types_x000D_
2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy_x000D_
3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above_x000D_
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels_x000D_
_x000D_
#Which Industry Trends Are Shaping the Future of the Onychomycosis Treatment Market?#_x000D_
To maintain their competitive advantage in the onychomycosis treatment market, key players like Moberg Pharma AB are concentrating on the development and approval of innovative products such as MOB-015. In June 2023, for example, the pharmaceutical company, based in Sweden, obtained authorization for MOB-015 in the European Union. This approval, the first of its kind globally for this innovative onychomycosis treatment, allows for its use in treating mild to moderate nail fungal infections in adults. The two Phase 3 trials that facilitated approval demonstrated a significantly better mycological cure rate (76% vs. 42% maximum for counterparts) and a noticeable overall cure rate for MOB-015, with no severe side effects. The product, a topical terbinafine formulation, delivers effective terbinafine concentrations to the nail and nail bed, reducing the risk of systemic exposure linked with oral terbinafine therapy._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Countries Are Leading the Onychomycosis Treatment Market?#_x000D_
North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the onychomycosis treatment market, and how is it changing globally?_x000D_
2. Who are the major companies in the onychomycosis treatment market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the onychomycosis treatment market right now?_x000D_
4. Which products or customer segments are growing the most in the onychomycosis treatment market?_x000D_
5. What factors are helping or slowing down the growth of the onychomycosis treatment market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
